Reassessing the Role of Carboplatin in Neoadjuvant Therapy for HER2-Positive Breast Cancer: Insights from the neoCARHP Trial
Expanding Targeted First-Line Options in BRAF V600E–Mutant Metastatic Colorectal Cancer: Insights From the BREAKWATER Trial
FDA Approves First Line HERNEXEOS® for HER2-mutant Advanced NSCLC
Expert Perspectives on MRD Testing in Multiple Myeloma
Redefining First-Line Maintenance in HR-Positive, HER2-Positive Metastatic Breast Cancer
Late Breaking Abstract – 2026 ASCO GI Symposium: Redefining First-Line Therapy in HER2-Positive Gastroesophageal Adenocarcinoma with Zanidatamab-Based Combinations
Reconsidering Menopausal Hormone Therapy in BRCA1/2 Carriers: Emerging Evidence Challenges Longstanding Concerns
FDA Approves First Line ENHERTU® plus PERJETA® for HER2-Positive Metastatic Breast Cancer
Neoadjuvant Niraparib Plus Dostarlimab in BRCA or PALB2-Mutated Triple Negative Breast Cancer: Phase II TBCRC 056 Results
Reassessing First-Line Chemotherapy Selection in Metastatic PDAC: Insights from the PASS-01 Trial
Therapeutic Prowess and Potential of Multifunctional Therapeutics: A Review of Bispecific Antibodies
FDA Approves Niraparib with Abiraterone Acetate plus Prednisone for BRCA2-Mutated mCSPC
HER2CLIMB-05: Redefining First-Line Maintenance Therapy in HER2-Positive Metastatic Breast Cancer
PHAROS: Long-Term Efficacy and Survival Outcomes with Encorafenib Plus Binimetinib in BRAF V600E–Mutant Metastatic NSCLC
Precision Medicine in Practice: Timely Use of Tumor NGS Remains Suboptimal in Common Cancers
Low Dose Aspirin Reduces Recurrence in Colorectal Cancer Patients with PI3K Pathway Alterations
FDA Approves KOMZIFTI® for Relapsed or Refractory Acute Myeloid Leukemia with a NPM1 mutation
Amivantamab–Lazertinib Combination Improves Overall Survival in EGFR-Mutated Advanced NSCLC
Precision Medicine in Practice: Timely Use of Tumor NGS Remains Suboptimal in Common Cancers
FDA Approval of INLURIYO® for ESR1-Mutated ER-positive, HER2-negative Metastatic Breast Cancer: Insights from EMBER-3
Bottom Ad
Advertisement
Subscribe
